| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2260 | 2019 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 534* | 2021 |
| SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. C COVIDSurg, C GlobalSurg Anaesthesia 77 (1), 28-39, 2022 | 100 | 2022 |
| New treatment strategies for HPV-positive head and neck cancer B Kofler, S Laban, CJ Busch, B Lörincz, R Knecht European Archives of Oto-Rhino-Laryngology 271, 1861-1867, 2014 | 94 | 2014 |
| Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma F Braig, M Voigtlaender, A Schieferdecker, CJ Busch, S Laban, T Grob, ... Oncotarget 7 (28), 42988, 2016 | 89 | 2016 |
| Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism F Braig, M Kriegs, M Voigtlaender, B Habel, T Grob, K Biskup, ... Cancer research 77 (5), 1188-1199, 2017 | 87 | 2017 |
| Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck J Thierauf, JA Veit, A Affolter, C Bergmann, J Grünow, S Laban, ... Melanoma research 25 (6), 503-509, 2015 | 72 | 2015 |
| HNSCC: tumour antigens and their targeting by immunotherapy A von Witzleben, C Wang, S Laban, N Savelyeva, CH Ottensmeier Cells 9 (9), 2103, 2020 | 70 | 2020 |
| LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck … JP Machiels, Y Tao, B Burtness, M Tahara, D Rischin, GV Alves, IPF Lima, ... Annals of Oncology 33, S1399, 2022 | 65 | 2022 |
| Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen‐A family and NY‐ESO‐1 cancer‐testis antigens represents an independent marker for poor survival in … S Laban, D Atanackovic, T Luetkens, R Knecht, CJ Busch, M Freytag, ... International journal of cancer 135 (5), 1142-1152, 2014 | 63 | 2014 |
| Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 M Hecht, AO Gostian, M Eckstein, S Rutzner, J von der Grün, T Illmer, ... Journal for immunotherapy of cancer 8 (2), 2020 | 61 | 2020 |
| NF-κB and its role in checkpoint control AC Betzler, MN Theodoraki, PJ Schuler, J Döscher, S Laban, ... International Journal of Molecular Sciences 21 (11), 3949, 2020 | 57 | 2020 |
| Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest M Kriegs, K Gurtner, Y Can, I Brammer, T Rieckmann, R Oertel, ... Radiotherapy and Oncology 115 (1), 120-127, 2015 | 57 | 2015 |
| Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? R Schwartz-Albiez, S Laban, S Eichmüller, M Kirschfink Autoimmunity reviews 7 (6), 491-495, 2008 | 53 | 2008 |
| HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1 CJ Busch, M Kriegs, S Laban, S Tribius, R Knecht, C Petersen, E Dikomey, ... Radiotherapy and oncology 108 (3), 495-499, 2013 | 52 | 2013 |
| 11q21 rearrangement is a frequent and highly specific genetic alteration in mucoepidermoid carcinoma TS Clauditz, A Gontarewicz, CJ Wang, A Münscher, S Laban, ... Diagnostic Molecular Pathology 21 (3), 134-137, 2012 | 50 | 2012 |
| Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer MN Theodoraki, K Lorenz, R Lotfi, D Fuerst, C Tsamadou, S Jaekle, ... Photodiagnosis and photodynamic therapy 19, 194-201, 2017 | 48 | 2017 |
| Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651 RI Haddad, K Harrington, M Tahara, RL Ferris, M Gillison, J Fayette, ... Journal of Clinical Oncology 41 (12), 2166-2180, 2023 | 46 | 2023 |
| Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation S Laban, L Steinmeister, L Gleißner, TJ Grob, R Grénman, C Petersen, ... Radiotherapy and Oncology 109 (2), 286-292, 2013 | 44 | 2013 |
| Clinical characteristics and outcomes of oropharyngeal carcinoma related to high‐risk non–human papillomavirus16 viral subtypes I Varier, BR Keeley, R Krupar, A Patsias, J Dong, N Gupta, AK Parasher, ... Head & Neck 38 (9), 1330-1337, 2016 | 43 | 2016 |
Thomas Karl HoffmannDept. Otorhinolaryngology, Head and Neck Surgery確認したメール アドレス: uniklinik-ulm.de
